In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report). The company’s shares opened today at $5.45.
According to TipRanks, Slutsky is a 4-star analyst with an average return of 11.8% and a 48.47% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Astria Therapeutics, TScan Therapeutics, and Ventyx Biosciences.
Currently, the analyst consensus on Ventyx Biosciences is a Strong Buy with an average price target of $11.71.
Based on Ventyx Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $54.03 million. In comparison, last year the company had a GAAP net loss of $30.46 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ventyx Biosciences (VTYX) Company Description:
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Read More on VTYX:
- Ventyx Biosciences price target lowered to $15 from $16 at Canaccord
- Largest borrow rate increases among liquid names
- Wells Fargo more bullish on Ventyx Biosciences, upgrades to Overweight
- Ventyx Biosciences upgraded to Overweight from Equal Weight at Wells Fargo
- Ventyx Biosciences upgraded to Outperform on new focus at Oppenheimer
